+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "SSC ILD Drug"

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Market Insight, Epidemiology and Market Forecast -2032 - Product Thumbnail Image

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • January 2022
  • 200 Pages
  • Global
From
Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

The SSC ILD Drug market is a segment of the respiratory drug market that focuses on the treatment of interstitial lung diseases (ILDs). These diseases are characterized by inflammation and scarring of the lungs, which can lead to difficulty breathing and other respiratory symptoms. The SSC ILD Drug market includes a variety of drugs, such as corticosteroids, immunosuppressants, and biologics, which are used to reduce inflammation and improve lung function. Additionally, the market includes drugs that are used to treat the symptoms of ILDs, such as bronchodilators and mucolytics. The SSC ILD Drug market is highly competitive, with many companies offering a range of products. Some of the major players in the market include AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Additionally, there are many smaller companies that specialize in the development and manufacture of ILD drugs. Show Less Read more